Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 44, 2009 - Issue 7
Submit an article Journal homepage
1,393
Views
246
CrossRef citations to date
0
Altmetric
Liver and Biliary Tract

Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial

John Willy Haukeland Faculty Division; Department of GastroenterologyCorrespondence[email protected]
, MD,
Zbigniew Konopski Department of Gastroenterology
,
Heidi Beate Eggesbø Department of Radiology, Aker University Hospital, Oslo, Norway
,
Hilde Løland von Volkmann Department of Gastroenterology, Haukeland University Hospital, Bergen, Norway
,
Gabriele Raschpichler Department of Gastroenterology, University Hospital Northern Norway, Tromsø, Norway
,
Kristian Bjøro Department of Gastroenterology and Hepatology, Rikshospitalet University Hospital, Oslo, Norway
,
Terese Haaland Department of Pathology, Ullevål University Hospital, Oslo, Norway
,
Else Marit Løberg Department of Pathology, Ullevål University Hospital, Oslo, Norway
&
Kåre Birkeland Department of Endocrinology, Aker University Hospital, Oslo, Norway; Faculty Division
 show all
Pages 853-860 | Received 26 Oct 2008, Published online: 21 Jul 2009

Citations (246)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (17)

Kelly D McCall, Debra Walter, Ashley Patton, Jean R Thuma, Maria C Courreges, Grzegorz Palczewski, Douglas J Goetz, Stephen Bergmeier & Frank L Schwartz. (2023) Anti-Inflammatory and Therapeutic Effects of a Novel Small-Molecule Inhibitor of Inflammation in a Male C57BL/6J Mouse Model of Obesity-Induced NAFLD/MAFLD. Journal of Inflammation Research 16, pages 5339-5366.
Read now
Qian-Long Wu, Shu-Xin Zeng, Jia-Ying Peng, Yi Yuan, Zhi Zhu, Zi-Chun Xie, Ze-Hong Huang, Jia-Shuan Huang, Jian-Mei Lai, Jin-an Chen & Min-Hua Lin. (2022) Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. Expert Review of Gastroenterology & Hepatology 16:9, pages 863-877.
Read now
Leila Zarei, Negin Farhad & Ata Abbasi. (2022) All-Trans Retinoic Acid (atRA) effectively improves liver steatosis in a rabbit model of high fat induced liver steatosis. Archives of Physiology and Biochemistry 128:4, pages 1010-1015.
Read now
Juana Carretero Gómez, Javier Ena, José Miguel Seguí Ripoll, Francisco Javier Carrasco-Sánchez, Ricardo Gómez Huelgas, José Manuel Casas Rojo, Manuel Suárez Tembra, Juan Jesús Carabantes Rueda & José Carlos Arévalo Lorido. (2021) Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity. Current Medical Research and Opinion 37:11, pages 1867-1873.
Read now
Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili & Stephen N. Davis. (2021) Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Review of Clinical Pharmacology 14:7, pages 837-852.
Read now
Atsuo Tahara & Toshiyuki Takasu. (2020) Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. Endocrine Research 45:2, pages 147-161.
Read now
Paola Dongiovanni, Raffaela Rametta, Marica Meroni & Luca Valenti. (2016) The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development – a potential therapeutic target?. Expert Review of Gastroenterology & Hepatology 10:2, pages 229-242.
Read now
N. U. Ashraf & T. A. Sheikh. (2015) Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radical Research 49:12, pages 1405-1418.
Read now
Alba Berlanga, Esther Guiu-Jurado, José Antonio Porras & Teresa Auguet. (2014) Molecular pathways in non-alcoholic fatty liver disease. Clinical and Experimental Gastroenterology 7, pages 221-239.
Read now
Samir Rouabhia, Natasa Milic & Ludovico Abenavoli. (2014) Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Review of Gastroenterology & Hepatology 8:4, pages 343-349.
Read now
Wataru Tomeno, Masato Yoneda, Kento Imajo, Yuji Ogawa, Takaomi Kessoku, Satoru Saito, Yuichiro Eguchi & Atsushi Nakajima. (2013) Emerging drugs for non-alcoholic steatohepatitis. Expert Opinion on Emerging Drugs 18:3, pages 279-290.
Read now
Claudia Della Corte, Anna Alisi, Raffaele Iorio, Arianna Alterio & Valerio Nobili. (2011) Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 12:12, pages 1901-1911.
Read now
Briohny W. Smith & Leon A. Adams. (2011) Non-alcoholic fatty liver disease. Critical Reviews in Clinical Laboratory Sciences 48:3, pages 97-113.
Read now
John Richard & Ildiko Lingvay. (2011) Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Review of Cardiovascular Therapy 9:3, pages 321-328.
Read now
Jelizaveta Sokolovska, Sergejs Isajevs, Olga Sugoka, Jelena Sharipova, Lasma Lauberte, Darja Svirina, Evita Rostoka, Tatjana Sjakste, Ivars Kalvinsh & Nikolajs Sjakste. (2010) Influence of metformin on GLUT1 gene and protein expression in rat streptozotocin diabetes mellitus model. Archives of Physiology and Biochemistry 116:3, pages 137-145.
Read now
. (2009) Postgraduate Courses. Scandinavian Journal of Gastroenterology 44:sup246, pages 1-41.
Read now
Lars Aabakken. (2009) This month in the Scandinavian Journal of Gastroenterology. Scandinavian Journal of Gastroenterology 44:7, pages 772-773.
Read now

Articles from other publishers (229)

Rachelle Haber, Fatima Zarzour, Malak Ghezzawi, Natalie Saadeh, Dania S. Bacha, Lama Al Jebbawi, Marlene Chakhtoura & Christos S. Mantzoros. (2024) The impact of metformin on weight and metabolic parameters in patients with obesity: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism 26:5, pages 1850-1867.
Crossref
Mustafa Oruc, Mustafa Emre Gedik, Meral Uner, Elif Ulug, Reyhan Nergiz Unal, Gurcan Gunaydin & Ahmet Bulent Dogrul. (2024) Effectiveness of metformin for the reversal of cold-ischemia-induced damage in hepatosteatosis. Clinics and Research in Hepatology and Gastroenterology 48:4, pages 102314.
Crossref
Federica Perazza, Laura Leoni, Santo Colosimo, Alessandra Musio, Giulia Bocedi, Michela D’Avino, Giulio Agnelli, Alba Nicastri, Chiara Rossetti, Federica Sacilotto, Giulio Marchesini, Maria Letizia Petroni & Federico Ravaioli. (2024) Metformin and the Liver: Unlocking the Full Therapeutic Potential. Metabolites 14:4, pages 186.
Crossref
Hao Wang, Qianqian Ma, Youpeng Chen, Ling Luo, Junzhao Ye & Bihui Zhong. (2024) Optimized strategy among diet, exercise, and pharmacological interventions for nonalcoholic fatty liver disease: A network meta‐analysis of randomized controlled trials. Obesity Reviews.
Crossref
Seung-Ju Hwang, Yu-Jin Choi, Jing-Hua Wang & Chang-Gue Son. (2024) Lactobacillus Casei-fermented Amomum Xanthioides Mitigates non-alcoholic fatty liver disease in a high-fat diet mice model. Biomedicine & Pharmacotherapy 172, pages 116250.
Crossref
Lukas Otero Sanchez, Yuping Chen, Guillaume Lassailly & Xiaolong Qi. (2023) Exploring the links between types 2 diabetes and liver‐related complications: A comprehensive review. United European Gastroenterology Journal 12:2, pages 240-251.
Crossref
Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi & Theodoros Androutsakos. (2023) The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. European Journal of Clinical Pharmacology 80:1, pages 127-150.
Crossref
Havva Afshari, Shokoofe Noori & Afshin Zarghi. (2023) A novel combination of metformin and resveratrol alleviates hepatic steatosis by activating autophagy through the cAMP/AMPK/SIRT1 signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology 396:11, pages 3135-3148.
Crossref
Partha Pratim Das & Subhash Medhi. (2023) Role of inflammasomes and cytokines in immune dysfunction of liver cirrhosis. Cytokine 170, pages 156347.
Crossref
Herbert Tilg, Christopher D Byrne & Giovanni Targher. (2023) NASH drug treatment development: challenges and lessons. The Lancet Gastroenterology & Hepatology 8:10, pages 943-954.
Crossref
Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, Simona Moffa, Teresa Mezza & Andrea Giaccari. (2023) Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis. Diabetes/Metabolism Research and Reviews 39:7.
Crossref
Kanokporn Sanpawithayakul & Márta Korbonits. (2023) Metabolic complications of glucocorticoids – Prevention by metformin. Annales d'Endocrinologie 84:4, pages 483-497.
Crossref
Min Jeong Park, Hayeon Kim, Myeong Gyu Kim & Kyungim Kim. (2023) Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis. Clinical and Molecular Hepatology 29:3, pages 693-704.
Crossref
Zhuo-Ya Zhang, Qi Yan, Wen-Hao Wu, Yuan Zhao, Hua Zhang & Jin Li. (2023) PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis. Journal of International Medical Research 51:6.
Crossref
Manash Pratim Pathak, Kalyani Pathak, Riya Saikia, Urvashee Gogoi, Pompy Patowary, Pronobesh Chattopadhyay & Aparoop Das. (2023) Therapeutic potential of bioactive phytoconstituents found in fruits in the treatment of non-alcoholic fatty liver disease: A comprehensive review. Heliyon 9:4, pages e15347.
Crossref
Bingli Liu, Jingyuan Xu, Linyao Lu, Lili Gao, Shengjuan Zhu, Yi Sui, Ting Cao & Tao Yang. (2023) Metformin induces pyroptosis in leptin receptor-defective hepatocytes via overactivation of the AMPK axis. Cell Death & Disease 14:2.
Crossref
Abdelilah Arredouani. 2022. Lifestyle-Related Diseases and Metabolic Syndrome. Lifestyle-Related Diseases and Metabolic Syndrome.
Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho & Nguan Soon Tan. (2022) Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. International Journal of Molecular Sciences 24:1, pages 158.
Crossref
Kuang-Hua Huang, Chiu-Hsiang Lee, Yih-Dih Cheng, Shuo-Yan Gau, Tung-Han Tsai, Ning-Jen Chung & Chien-Ying Lee. (2022) Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study. Frontiers in Endocrinology 13.
Crossref
Kevan Josloff, Jacob Beiriger, Adnan Khan, Richard J. Gawel, Richard S. Kirby, Aaron D. Kendrick, Abhinav K. Rao, Roy X. Wang, Michelle M. Schafer, Margaret E. Pearce, Kashyap Chauhan, Yash B. Shah, Gregary D. Marhefka & Dina Halegoua-DeMarzio. (2022) Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. Journal of Cardiovascular Development and Disease 9:12, pages 419.
Crossref
Yuanshe Huang, Xiaodong Wang, Chen Yan, Chen LiLidan Zhang, Lai Zhang, E Liang, Tianlei Liu & Jingxin Mao. (2022) Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine 101:43, pages e31437.
Crossref
Ming-Hui Yang, Wei-You Li, Ching-Fen Wu, Yi-Ching Lee, Allan Yi-Nan Chen, Yu-Chang Tyan & Yi-Ming Arthur Chen. (2022) Reversal of High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Metformin Combined with PGG, an Inducer of Glycine N-Methyltransferase. International Journal of Molecular Sciences 23:17, pages 10072.
Crossref
Sevket Balta. (2022) Atherosclerosis and Non-Alcoholic Fatty Liver Disease. Angiology 73:8, pages 701-711.
Crossref
Dunya Tomic, Jonathan E. Shaw & Dianna J. Magliano. (2022) The burden and risks of emerging complications of diabetes mellitus. Nature Reviews Endocrinology 18:9, pages 525-539.
Crossref
Cosmina-Theodora Diaconu & Cristian Guja. (2022) Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies. Journal of Clinical Medicine 11:17, pages 5144.
Crossref
Shivaram Prasad Singh, Reshu Khandelwal & Anuradha Supun Dassanayake. (2022) Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist. Euroasian Journal of Hepato-Gastroenterology 12:S1, pages S37-S40.
Crossref
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi & Farhad Zamani. (2022) A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Frontiers in Medicine 9.
Crossref
Shaza Asif, Ri Youn Kim, Thet Fatica, Jordan Sim, Xiaoling Zhao, Yena Oh, Alix Denoncourt, Angela C. Cheung, Michael Downey, Erin E. Mulvihill & Kyoung-Han Kim. (2022) Hmgcs2-mediated ketogenesis modulates high-fat diet-induced hepatosteatosis. Molecular Metabolism 61, pages 101494.
Crossref
Mohsen Arabi, Raheleh Alimoradzadeh, Alireza Makian, Seyed Javad Shariat Nabavi, Farshad Divsalar & Mitra Kazemi Jahromi. (2022) Non-alcoholic Steatohepatitis Diagnosis and Treatment Medical and Surgery, Based on Guideline Updates: A Mini Review. Journal of Health Reports and Technology 8:3.
Crossref
Alba Rojano-Toimil, Jesús Rivera-Esteban, Ramiro Manzano-Nuñez, Juan Bañares, David Martinez Selva, Pablo Gabriel-Medina, Roser Ferrer, Juan M Pericàs & Andreea Ciudin. (2022) When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. Journal of Clinical Medicine 11:12, pages 3286.
Crossref
Giovanna Beauchamp, Mary M. Barr, Ariana Vergara, Ambika Ashraf & Fernando Bril. (2022) Treatment of hyperglycemia not associated with NAFLD improvement in children with type 2 diabetes mellitus. International Journal of Pediatrics and Adolescent Medicine 9:2, pages 83-88.
Crossref
Alajos Pár, István Wittmann & Gabriella Pár. (2022) A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.. Orvosi Hetilap 163:22, pages 855-862.
Crossref
Ali Akbar Hajiagha Mohammadi, Sina Khajeh Jahromi, Somayeh Ahmadi Gooraji & Ali Bastani. (2022) Comparison of the Therapeutic Effects of Melatonin, Metformin and Vitamin E on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Journal of Advances in Medical and Biomedical Research 30:140, pages 232-240.
Crossref
Elaine Chow, Aimin Yang, Colin H. L. Chung & Juliana C. N. Chan. (2022) A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer. Pharmaceuticals 15:4, pages 442.
Crossref
Marcin Kosmalski, Sylwia Ziółkowska, Piotr Czarny, Janusz Szemraj & Tadeusz Pietras. (2022) The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Journal of Clinical Medicine 11:5, pages 1375.
Crossref
Sabine Kahl, Jennifer Pützer & Michael Roden. (2021) Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis. Seminars in Liver Disease 42:01, pages 048-060.
Crossref
Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico, Gianluca Svegliati-Baroni, Luca Valenti, Massimo Federici, Francesco Purrello, Ferdinando Carlo Sasso, Giovanni Targher, Luca Busetto, Maria Letizia Petroni, Ferruccio Santini, Calogero Cammà & Agostino Colli. (2022) Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive and Liver Disease 54:2, pages 170-182.
Crossref
Kemal Ozan Lule, Ersin Akarsu, Zeynel Abidin Sayiner, Nezihe Otay Lule, Sibel Oguzkan Balci, Can Demirel, Zehra Bozdag, Murat Korkmaz & Ibrahim Yilmaz. (2022) The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules. Inflammopharmacology 30:1, pages 243-250.
Crossref
Yasser Fouad, Gamal Esmat, Reda Elwakil, Serag Zakaria, Ayman Yosry, Imam Waked, Maissa El-Razky, Wahid Doss, Magdy El-Serafy, Ebraheem Mostafa, Mahmood Anees, MohamedA Sakr, Nadia AbdelAty, Ashraf Omar, Samy Zaki, Amgad Al-zahaby, Hamdy Mahfouz, Maysaa Abdalla, Mahmoud Albendary, Abdel-Khalek Hamed, Ahmed Gomaa, Adel Hasan, Sherif Abdel-baky, Medhat El sahhar, Gamal Shiha, Dina Attia, Ebada Saeed, Enas Kamal, Shamardan Bazeed, Mai Mehrez, Shereen Abdelaleem, Yasmine Gaber, Mohammed Abdallah, Asmaa Salama, DoaaA Tawab & Shaymaa Nafady. (2022) The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi Journal of Gastroenterology 28:1, pages 3.
Crossref
Zeinab El Rashed, Elena Grasselli, Hala Khalifeh, Laura Canesi & Ilaria Demori. (2020) Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. Planta Medica 88:01, pages 9-19.
Crossref
Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico, Gianluca Svegliati-Baroni, Luca Valenti, Massimo Federici, Francesco Purrello, Ferdinando Carlo Sasso, Giovanni Targher, Luca Busetto, Maria Letizia Petroni, Ferruccio Santini, Calogero Cammà & Agostino Colli. (2022) Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutrition, Metabolism and Cardiovascular Diseases 32:1, pages 1-16.
Crossref
Maria Apostolopoulou & Michael Roden. 2022. Nicht-alkoholische Fettlebererkrankung. Nicht-alkoholische Fettlebererkrankung 211 225 .
Jing-Hua Wang, Seung-Ju Hwang, Dong-Woo Lim & Chang-Gue Son. (2021) Cynanchum atratum Alleviates Non-Alcoholic Fatty Liver by Balancing Lipogenesis and Fatty Acid Oxidation in a High-Fat, High-Fructose Diet Mice Model. Cells 11:1, pages 23.
Crossref
. (2021) Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity 27:5, pages 1603-1619.
Crossref
Sepideh Shekari, Fatemeh Khonsha, Mohammad Rahmati-Yamchi, Hamid R. Nejabati & Ali Mota. (2021) Vanillic Acid and Non-Alcoholic Fatty Liver Disease: A Focus on AMPK in Adipose and Liver Tissues. Current Pharmaceutical Design 27:46, pages 4686-4692.
Crossref
Kanokwan Pinyopornpanish, Apinya Leerapun, Kanokporn Pinyopornpanish & Nipon Chattipakorn. (2021) Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. Gut and Liver 15:6, pages 827-840.
Crossref
Mohammad Bagher Majnooni, Mari Ataee, Gholamreza Bahrami, Fatemeh Heydarpour, Ina Yosifova Aneva, Mohammad Hosein Farzaei & Touraj Ahmadi‐Juoibari. (2021) The effects of co‐administration of artichoke leaf extract supplementation with metformin and vitamin E in patients with nonalcoholic fatty liver disease: A randomized clinical trial. Phytotherapy Research 35:11, pages 6324-6334.
Crossref
Brittany B. Dennis, Sandy Sallam, Brandon J. Perumpail, Neha D. Shah, Donghee Kim, George Cholankeril & Aijaz Ahmed. (2021) Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 55:9, pages 747-756.
Crossref
Yi-Zhou Huang, Gang-Yi Yang, Cong Wang, Xing-Yu Chen & Li-Li Zhang. (2021) Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis. World Journal of Diabetes 12:9, pages 1576-1586.
Crossref
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne & Michael Roden. (2021) The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nature Reviews Gastroenterology & Hepatology 18:9, pages 599-612.
Crossref
Francisca dos Santos Coelho, Marta Borges‐Canha, Madalena von Hafe, João Sérgio Neves, Catarina Vale, Ana Rita Leite, Davide Carvalho & Adelino Leite‐Moreira. (2020) Effects of sodium‐glucose co‐transporter 2 inhibitors on liver parameters and steatosis: A meta‐analysis of randomized clinical trials. Diabetes/Metabolism Research and Reviews 37:6.
Crossref
Kalliopi Pafili & Michael Roden. (2021) Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Molecular Metabolism 50, pages 101122.
Crossref
Maryam Mahjoubin-Tehran, Antonio De Vincentis, Dimitri P. Mikhailidis, Stephen L. Atkin, Christos S. Mantzoros, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2021) Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism 50, pages 101049.
Crossref
Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee & Yong Kyun Cho. (2021) KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology 27:3, pages 363-401.
Crossref
T.I. Yefimenko & M.R. Mykytyuk. (2021) Non-alcoholic fatty liver disease: time for changes. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 17:4, pages 334-345.
Crossref
Francesca Fianchi, Antonio Liguori, Antonio Gasbarrini, Antonio Grieco & Luca Miele. (2021) Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut–Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. International Journal of Molecular Sciences 22:12, pages 6485.
Crossref
Emir Muzurović, Dimitri P. Mikhailidis & Christos Mantzoros. (2021) Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 119, pages 154770.
Crossref
Lukas Hartl, Joshua Elias, Gerhard Prager, Thomas Reiberger & Lukas W Unger. (2021) Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World Journal of Gastroenterology 27:19, pages 2281-2298.
Crossref
Anna Roskilly, Amy Hicks, Eleanor J. Taylor, Rebecca Jones, Richard Parker & Ian A. Rowe. (2020) Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis. Liver International 41:5, pages 982-995.
Crossref
Cyrielle Caussy, Adrien Aubin & Rohit Loomba. (2021) The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports 21:5.
Crossref
Maoyan Wu, Huiwen Xu, Jingyu Liu, Xiaozhen Tan, Shengrong Wan, Man Guo, Yang Long & Yong Xu. (2021) Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. Journal of Diabetes Research 2021, pages 1-11.
Crossref
Revathy Carnagarin, Kearney Tan, Leon Adams, Vance B. Matthews, Marcio G. Kiuchi, Leslie Marisol Lugo Gavidia, Gavin W. Lambert, Elisabeth A. Lambert, Lakshini Y. Herat & Markus P. Schlaich. (2021) Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation. International Journal of Molecular Sciences 22:8, pages 4241.
Crossref
Alexandra Jichitu, Simona Bungau, Ana Maria Alexandra Stanescu, Cosmin Mihai Vesa, Mirela Marioara Toma, Cristiana Bustea, Stela Iurciuc, Marius Rus, Nicolae Bacalbasa & Camelia Cristina Diaconu. (2021) Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics 11:4, pages 689.
Crossref
Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante-Mangoni & Rosa Zampino. (2021) Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. Journal of Clinical Medicine 10:8, pages 1569.
Crossref
Samar H. Gerges, Sara A. Wahdan, Doaa A. Elsherbiny & Ebtehal El-Demerdash. (2021) Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sciences 271, pages 119220.
Crossref
Jingxuan Lian & Jianfang Fu. (2021) Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. Frontiers in Endocrinology 12.
Crossref
Reem Abou Assi, Ibrahim M. Abdulbaqi & Chan Siok Yee. (2021) The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals 14:3, pages 215.
Crossref
Zhe Zheng, Yue Li, Siyuan Fan, Jie An, Xi Luo, Minglu Liang, Feng Zhu & Kai Huang. (2021) WW domain-binding protein 2 overexpression prevents diet-induced liver steatosis and insulin resistance through AMPKβ1. Cell Death & Disease 12:3.
Crossref
Deepu David & Chundamannil E. Eapen. (2021) What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?. Journal of Clinical and Experimental Hepatology 11:2, pages 232-238.
Crossref
Marinko Marušić, Matej Paić, Mia Knobloch & Ana-Marija Liberati Pršo. (2021) NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Canadian Journal of Gastroenterology and Hepatology 2021, pages 1-9.
Crossref
I. I. Dedov, M. V. Shestakova, G. A. Melnichenko, N. V. Mazurina, E. N. Andreeva, I. Z. Bondarenko, Z. R. Gusova, F. K. Dzgoeva, M. S. Eliseev, E. V. Ershova, M. V. Zhuravleva, T. A. Zakharchuk, V. A. Isakov, M. V. Klepikova, K. A. Komshilova, V. S. Krysanova, S. V. Nedogoda, A. M. Novikova, O. D. Ostroumova, A. P. Pereverzev, R. V. Rozhivanov, T. I. Romantsova, L. A. Ruyatkina, A. S. Salasyuk, A. N. Sasunova, S. A. Smetanina, A. V. Starodubova, L. A. Suplotova, O. N. Tkacheva, E. A. Troshina, M. V. Khamoshina, S. M. Chechelnitskaya, E. A. Shestakova & E. V. Sheremet’eva. (2021) INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and metabolism 18:1, pages 5-99.
Crossref
Beniamino PALMIERI, Veronica CORAZZARI, Diana G. PANARIELLO BRASILE, Vincenzo SANGIOVANNI & Maria VADALÀ. (2021) Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. Minerva Gastroenterologica e Dietologica 66:4.
Crossref
Paul Middleton & Nikhil Vergis. (2021) Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation. Therapeutic Advances in Gastroenterology 14, pages 175628482110313.
Crossref
Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn & Seung Up Kim. (2021) Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. Journal of Diabetes and its Complications 35:1, pages 107747.
Crossref
Amélio F. Godoy-Matos, Wellington S. Silva Júnior & Cynthia M. Valerio. (2020) NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome 12:1.
Crossref
Mohammed Eslam, Shiv K. Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani, Shahinul Alam, Yock Young Dan, Jia-Horng Kao, Saeed Hamid, Ian Homer Cua, Wah-Kheong Chan, Diana Payawal, Soek-Siam Tan, Tawesak Tanwandee, Leon A. Adams, Manoj Kumar, Masao Omata & Jacob George. (2020) The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology International 14:6, pages 889-919.
Crossref
A. Mantovani, C.D. Byrne, E. Scorletti, C.S. Mantzoros & G. Targher. (2020) Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & Metabolism 46:6, pages 427-441.
Crossref
Alejandro Campos-Murguía, Astrid Ruiz-Margáin, José A González-Regueiro & Ricardo U Macías-Rodríguez. (2020) Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World Journal of Gastroenterology 26:39, pages 5919-5943.
Crossref
Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau & Aysha Aslam. (2020) A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Microorganisms 8:10, pages 1526.
Crossref
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili & Michael Roden. (2020) Metabolic liver disease in diabetes – From mechanisms to clinical trials. Metabolism 111, pages 154299.
Crossref
Waihong Chung, Kittichai Promrat & Jack Wands. (2020) Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology 12:9, pages 533-557.
Crossref
Phei Oon Tan, Nazri Mustaffa, Soek Siam Tan & Yeong Yeh Lee. (2020) Diagnosis and Management of Fatty Liver. Journal of the Royal College of Physicians of Edinburgh 50:3, pages 256-261.
Crossref
Mohammad Jalali, Mehran Rahimlou, Marzieh Mahmoodi, Seyedeh Parisa Moosavian, Michael E. Symonds, Ronak Jalali, Morteza Zare, Mohammad Hadi Imanieh & Cristina Stasi. (2020) The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacological Research 159, pages 104799.
Crossref
Jennifer Pützer & Sabine Kahl. (2020) Nichtalkoholische Fettlebererkrankung und Typ‑2‑DiabetesNon-alcoholic fatty liver disease and type 2 diabetes. Der Diabetologe 16:6, pages 574-583.
Crossref
Gehan H. HeebaReham M. El-DeenRania G. Abdel-latifMohamed M.A. Khalifa. (2020) Combined treatments with metformin and phosphodiesterase inhibitors alleviate nonalcoholic fatty liver disease in high-fat diet fed rats: a comparative study. Canadian Journal of Physiology and Pharmacology 98:8, pages 498-505.
Crossref
Faisal M Sanai, Faisal Abaalkhail, Fuad Hasan, Muhammad Hamed Farooqi, Nawal Al Nahdi & Zobair M Younossi. (2020) Management of nonalcoholic fatty liver disease in the Middle East. World Journal of Gastroenterology 26:25, pages 3528-3541.
Crossref
Chin-Yu Liu, Ting-Chia Chang, Shyh-Hsiang Lin, Sheng-Tang Wu, Tai-Lung Cha & Chih-Wei Tsao. (2020) Metformin Ameliorates Testicular Function and Spermatogenesis in Male Mice with High-Fat and High-Cholesterol Diet-Induced Obesity. Nutrients 12:7, pages 1932.
Crossref
Yana Geng, Alejandra Hernández Villanueva, Asmaa Oun, Manon Buist-Homan, Hans Blokzijl, Klaas Nico Faber, Amalia Dolga & Han Moshage. (2020) Protective effect of metformin against palmitate-induced hepatic cell death. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1866:3, pages 165621.
Crossref
Chelsea S. Pan & Takara L. Stanley. (2020) Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Frontiers in Endocrinology 11.
Crossref
Paul Horn & Philip N. Newsome. (2019) Commentary: advances in the pharmacotherapy of NASH—anti‐diabetic drugs and beyond. Alimentary Pharmacology & Therapeutics 51:1, pages 199-200.
Crossref
Marie Detrait, Eva de Berranger, Remy Dulery, Anne-Lise Ménard, Sylvain Thépot, Selami Kocak Toprak, Pascal Turlure, Ibrahim Yakoub-Agha & Thierry Guillaume. (2020) Complications hépatobiliaires dans le contexte de l’allogreffe de cellules hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). Bulletin du Cancer 107:1, pages S18-S27.
Crossref
Christiane Stern & Vlad Ratziu. 2020. Non-Alcoholic Fatty Liver Disease. Non-Alcoholic Fatty Liver Disease 309 327 .
Ian Blazina & Shelley Selph. (2019) Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Systematic Reviews 8:1.
Crossref
Yi Sui, Xianhe Kong, Rongrong Fan, Yanbin Ye, Haiyan Mai, Shuyu Zhuo, Wei Lu, Peishan Ruan, Shi Fang & Tao Yang. (2019) Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats. Diabetology & Metabolic Syndrome 11:1.
Crossref
Sepideh Ahadi, Afshin Gharekhani & Afshin Shiva. (2019) Treatments of nonalcoholic fatty liver disease in adults who have no other illness: A Review article. Arab Journal of Gastroenterology 20:4, pages 189-197.
Crossref
Lynda Bourebaba & Krzysztof Marycz. (2019) Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review. Journal of Clinical Medicine 8:12, pages 2033.
Crossref
Selene de Jesús Acosta-Cota, Elsa Maribel Aguilar-Medina, Rosalío Ramos-Payán, José Guadalupe Rendón Maldonado, José Geovanni Romero-Quintana, Julio Montes-Avila, Juan I. Sarmiento-Sánchez, Carolina Gabriela Plazas-Guerrero, Marcela J. Vergara-Jiménez, Araceli Sánchez-López, David Centurión & Ulises Osuna-Martínez. (2019) Therapeutic effect of treatment with metformin and/or 4-hydroxychalcone in male Wistar rats with nonalcoholic fatty liver disease. European Journal of Pharmacology 863, pages 172699.
Crossref
Ravirajsinh N. Jadeja, Xin Chu, Craig Wood, Manuela Bartoli & Sandeep Khurana. (2019) M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKKβ/AMPK pathway. Biochemical Pharmacology 169, pages 113613.
Crossref
Chen, Zhuang, Sng, Tan & Wahli. (2019) The Potential of the FSP1cre-Pparb/d−/− Mouse Model for Studying Juvenile NAFLD. International Journal of Molecular Sciences 20:20, pages 5115.
Crossref
Georgios Tsoulfas. (2019) Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we. World Journal of Gastroenterology 25:29, pages 3842-3848.
Crossref
Zheng Li, Yan Li, Hui‐Xia Zhang, Jian‐Ru Guo, Christopher Wai Kei Lam, Cai‐Yun Wang & Wei Zhang. (2019) Mitochondria‐Mediated Pathogenesis and Therapeutics for Non‐Alcoholic Fatty Liver Disease. Molecular Nutrition & Food Research 63:16.
Crossref
Gábor ZsóriDóra IllésEmese IványKlára KosárGábor HolzingerMáté TajtiEszter PálinkásGéza SzabovikAndrás NagyAndrás PalkóLászló Czakó. (2019) In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metabolic Syndrome and Related Disorders 17:5, pages 289-295.
Crossref
Simona Marchisello, Antonino Di Pino, Roberto Scicali, Francesca Urbano, Salvatore Piro, Francesco Purrello & Agata Maria Rabuazzo. (2019) Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. International Journal of Molecular Sciences 20:8, pages 1948.
Crossref
Charlotte J. Green, Thomas Marjot, Jeremy W. Tomlinson & Leanne Hodson. (2018) Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?. Diabetes, Obesity and Metabolism 21:4, pages 749-760.
Crossref
Gabriela Handzlik, Michał Holecki, Joanna Kozaczka, Michał Kukla, Katarzyna Wyskida, Leszek Kędzierski, Krzysztof Pawlicki & Jan Duława. (2019) Evaluation of metformin therapy using controlled attenuation parameter and transient elastography in patients with non-alcoholic fatty liver disease. Pharmacological Reports 71:2, pages 183-188.
Crossref
Ma Ai Thanda Han, Osama Altayar, Shadi Hamdeh, Varun Takyar, Yaron Rotman, Ohad Etzion, Eric Lefebvre, Rifaat Safadi, Vlad Ratziu, Larry J. Prokop, Mohammad Hassan Murad & Mazen Noureddin. (2019) Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 17:4, pages 616-629.e26.
Crossref
Vlad RatziuMarwan GhabrilManuel Romero-GomezGianluca Svegliati-Baroni. (2019) Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 103:1, pages 28-38.
Crossref
Emmanuel TsochatzisAudrey Coilly, Silvio NadalinJosh LevistkyYaman TokatMark GhobrialJohn KlinckMarina Berenguer. (2019) International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. Transplantation 103:1, pages 45-56.
Crossref
Laurence Poekes, Justine Gillard, Geoffrey C. Farrell, Yves Horsmans & Isabelle A. Leclercq. (2019) Activation of brown adipose tissue enhances the efficacy of caloric restriction for treatment of nonalcoholic steatohepatitis. Laboratory Investigation 99:1, pages 4-16.
Crossref
SM Jeyakumar & A Vajreswari. 2019. Dietary Interventions in Liver Disease. Dietary Interventions in Liver Disease 373 389 .
Lisa K. Koch & Matthew M. Yeh. (2018) Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging. Annals of Diagnostic Pathology 37, pages 83-90.
Crossref
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola & Salvatore Petta. (2018) Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals 11:4, pages 121.
Crossref
Rosann Cholankeril, Vikram Patel, Brandon Perumpail, Eric Yoo, Umair Iqbal, Sandy Sallam, Neha Shah, Waiyee Kwong, Donghee Kim & Aijaz Ahmed. (2018) Anti-Diabetic Medications for the Pharmacologic Management of NAFLD. Diseases 6:4, pages 93.
Crossref
Sherin E. Mathews, Rekha B. Kumar & Alpana P. Shukla. (2018) Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. Current Opinion in Endocrinology, Diabetes & Obesity 25:5, pages 315-320.
Crossref
Simona Leoni, Francesco Tovoli, Lucia Napoli, Ilaria Serio, Silvia Ferri & Luigi Bolondi. (2018) Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World Journal of Gastroenterology 24:30, pages 3361-3373.
Crossref
Carrie R. Wong & Joseph K. Lim. (2018) The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. Clinical Liver Disease 12:2, pages 39-44.
Crossref
Heather S. Snyder, Sami A. Sakaan, Katherine L. March, Osama Siddique, Rosann Cholankeril, Carolyn D. Cummings, Chiran Gadiparthi, Sanjaya K. Satapathy, Aijaz Ahmed & George Cholankeril. (2018) Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. Journal of Clinical and Translational Hepatology 6:2, pages 1-7.
Crossref
Jiapeng Chen, Alexandra Montagner, Nguan Tan & Walter Wahli. (2018) Insights into the Role of PPARβ/δ in NAFLD. International Journal of Molecular Sciences 19:7, pages 1893.
Crossref
Ashley Patton, Tyler Church, Caroline Wilson, Jean Thuma, Douglas J Goetz, Darlene E Berryman, Edward O List, Frank Schwartz & Kelly D McCall. (2018) Phenylmethimazole abrogates diet-induced inflammation, glucose intolerance and NAFLD. Journal of Endocrinology 237:3, pages 337-351.
Crossref
N. Chalasani, R. Vuppalanchi, M. Rinella, M. S. Middleton, M. S. Siddiqui, A. S. BarrittIVIV, O. Kolterman, O. Flores, C. Alonso, M. Iruarrizaga‐Lejarreta, R. Gil‐Redondo, C. B. Sirlin & M. B. Zemel. (2018) Randomised clinical trial: a leucine‐metformin‐sildenafil combination ( NS ‐0200) vs placebo in patients with non‐alcoholic fatty liver disease . Alimentary Pharmacology & Therapeutics 47:12, pages 1639-1651.
Crossref
Sara Shojaei Zarghani, Samin Abbaszadeh, Mohammad Alizadeh, Maryam Rameshrad, Alireza Garjani & Hamid Soraya. (2018) The Eeffect of Metformin Combined with Calcium-Vitamin D3 Against Diet-Induced Nonalcoholic Fatty Liver Disease. Advanced Pharmaceutical Bulletin 8:1, pages 97-105.
Crossref
Giovanni Targher, Amedeo Lonardo & Christopher D. Byrne. (2017) Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nature Reviews Endocrinology 14:2, pages 99-114.
Crossref
Chun Kit Hung & Henry C. BodenheimerJr.Jr.. (2018) Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinics in Liver Disease 22:1, pages 175-187.
Crossref
Elizabeth P. Mills, K. Paige D. Brown, Jennifer D. Smith, Phillip W. Vang & Katie Trotta. (2017) Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. Therapeutic Advances in Endocrinology and Metabolism 9:1, pages 15-28.
Crossref
Shiv Chitturi, Vincent Wai‐Sun Wong, Wah‐Kheong Chan, Grace Lai‐Hung Wong, Simon Kin‐Hung Wong, Jose Sollano, Yen‐Hsuan Ni, Chun‐Jen Liu, Yu‐Cheng Lin, Laurentius Adrianto Lesmana, Seung Up Kim, Etsuko Hashimoto, Masahide Hamaguchi, Khean‐Lee Goh, Jiangao Fan, Ajay Duseja, Yock Young Dan, Yogesh Chawla, Geoff Farrell & Henry Lik‐Yuen Chan. (2017) The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups. Journal of Gastroenterology and Hepatology 33:1, pages 86-98.
Crossref
Naga Chalasani, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, Elizabeth M. Brunt & Arun J. Sanyal. (2017) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:1, pages 328-357.
Crossref
Ahad Eshraghian. (2017) Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World Journal of Gastroenterology 23:42, pages 7495-7504.
Crossref
Niharika Samala, Sarah A. Tersey, Naga Chalasani, Ryan M. Anderson & Raghavendra G. Mirmira. (2017) Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase. Journal of Diabetes and its Complications 31:11, pages 1630-1637.
Crossref
Sukhpreet Singh, Natalia A Osna & Kusum K Kharbanda. (2017) Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World Journal of Gastroenterology 23:36, pages 6549-6570.
Crossref
Adnan Said & Ahmed Akhter. (2017) Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis. Annals of Hepatology 16:4, pages 538-547.
Crossref
Rosa Lombardi, Simona Onali, Douglas Thorburn, Brian R Davidson, Kurinchi Selvan Gurusamy & Emmanuel Tsochatzis. (2017) Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD). Cochrane Database of Systematic Reviews 2017:4.
Crossref
Xu Li, Xiaocong Wang & Pujun Gao. (2017) Diabetes Mellitus and Risk of Hepatocellular Carcinoma. BioMed Research International 2017, pages 1-10.
Crossref
Herbert Tilg, Alexander R. Moschen & Michael Roden. (2016) NAFLD and diabetes mellitus. Nature Reviews Gastroenterology & Hepatology 14:1, pages 32-42.
Crossref
Ahmed Akhter, Abhishek Pulla & Adnan Said. (2016) Revisión de los tratamientos farmacológicos actuales y futuros de la esteatohepatitis no alcohólica. Clinical Liver Disease 8:S1, pages S34-S38.
Crossref
Brennan K. Smith, Katarina Marcinko, Eric M. Desjardins, James S. Lally, Rebecca J. Ford & Gregory R. Steinberg. (2016) Treatment of nonalcoholic fatty liver disease: role of AMPK. American Journal of Physiology-Endocrinology and Metabolism 311:4, pages E730-E740.
Crossref
Ratree Sawangjit, Bunchai Chongmelaxme, Pochamana Phisalprapa, Surasak Saokaew, Ammarin Thakkinstian, Kris V. Kowdley & Nathorn Chaiyakunapruk. (2016) Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD). Medicine 95:32, pages e4529.
Crossref
Jonathan Temple, Paul Cordero, Jiawei Li, Vi Nguyen & Jude Oben. (2016) A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. International Journal of Molecular Sciences 17:6, pages 947.
Crossref
. (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology 64:6, pages 1388-1402.
Crossref
G. Targher, G. Marchesini & C.D. Byrne. (2016) Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. Diabetes & Metabolism 42:3, pages 142-156.
Crossref
. (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:6, pages 1121-1140.
Crossref
Hong Xu, Yang Zhou, Yongxia Liu, Jian Ping, Qiyang Shou, Fangming Chen & Ru Ruo. (2016) Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. Journal of Endocrinology 229:2, pages 133-144.
Crossref
Eduardo García Díaz, Danila Guagnozzi, Verónica Gutiérrez, Carmen Mendoza, Cristina Maza, Yulene Larrañaga, Dolores Perdomo, Teresa Godoy & Ghalli Taleb. (2016) Efecto de las terapias incretínicas comparadas con pioglitazona y gliclazida en la esteatosis hepática no alcohólica de los pacientes diabéticos no controlados solo con metformina: estudio observacional piloto. Endocrinología y Nutrición 63:5, pages 194-201.
Crossref
Eduardo García Díaz, Danila Guagnozzi, Verónica Gutiérrez, Carmen Mendoza, Cristina Maza, Yulene Larrañaga, Dolores Perdomo, Teresa Godoy & Ghalli Taleb. (2016) Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. Endocrinología y Nutrición (English Edition) 63:5, pages 194-201.
Crossref
Bilal Hameed & Norah Terrault. (2016) Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 20:2, pages 365-385.
Crossref
David E. Kleiner & Hala R. Makhlouf. (2016) Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clinics in Liver Disease 20:2, pages 293-312.
Crossref
Swaytha Ganesh & Vinod K. Rustgi. (2016) Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 20:2, pages 351-364.
Crossref
Natasha McDonald & Jonathan Fallowfield. 2016. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease. Clinical Dilemmas in Non‐Alcoholic Fatty Liver Disease 218 225 .
Wenjuan Tang, Qianyue Xu, Ting Hong, Guoyu Tong, Wenhuan Feng, Shanmei Shen, Yan Bi & Dalong Zhu. (2015) Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized and non‐randomized studies. Diabetes/Metabolism Research and Reviews 32:2, pages 200-216.
Crossref
Mary E. Rinella, Zurabi Lominadze, Rohit Loomba, Michael Charlton, Brent A. Neuschwander-Tetri, Stephen H. Caldwell, Kris Kowdley & Stephen A. Harrison. (2015) Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therapeutic Advances in Gastroenterology 9:1, pages 4-12.
Crossref
. (2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts 9:2, pages 65-90.
Crossref
Samer Gawrieh & Naga Chalasani. 2016. Alcoholic and Non-Alcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease 313 337 .
Ahmed Akhter, Abhishek Pulla & Adnan Said. (2016) Review of current and potential future pharmacological treatments in nonalcoholic steatohepatitis. Clinical Liver Disease 7:1, pages 11-14.
Crossref
Soo Lim, Tae Jung Oh & Kwang Kon Koh. (2015) Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. International Journal of Cardiology 201, pages 408-414.
Crossref
M. Shadab Siddiqui & Arun J. Sanyal. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology 2056 2069 .
Melissa A. LindenKristi T. LopezJustin A. FletcherE. Matthew MorrisGrace M. MeersSameer SiddiqueM. Harold LaughlinJames R. SowersJohn P. ThyfaultJamal A. IbdahR. Scott Rector. (2015) Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats. Applied Physiology, Nutrition, and Metabolism 40:10, pages 1038-1047.
Crossref
Münevver Demir, Sonja Lang & Hans‐Michael Steffen. (2015) Nonalcoholic fatty liver disease – current status and future directions. Journal of Digestive Diseases 16:10, pages 541-557.
Crossref
Shihui Chen, Xiaolan Zhao, Jing Wan, Li Ran, Yu Qin, Xiaofang Wang, Yanxiang Gao, Furong Shu, Yong Zhang, Peng Liu, Qianyong Zhang, Jundong Zhu & Mantian Mi. (2015) Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacological Research 99, pages 74-81.
Crossref
Juan Zheng, Shih-Lung Woo, Xiang Hu, Rachel Botchlett, Lulu Chen, Yuqing Huo & Chaodong Wu. (2015) Metformin and metabolic diseases: a focus on hepatic aspects. Frontiers of Medicine 9:2, pages 173-186.
Crossref
Timothy Hardy, Quentin M. Anstee & Christopher P. Day. (2015) Nonalcoholic fatty liver disease. Current Opinion in Gastroenterology 31:3, pages 175-183.
Crossref
George Q. Li, Moon‐Sun Kim, Fangming Jin & Jun‐Lae Cho. 2015. Phytotherapies. Phytotherapies 429 463 .
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano & Tooru Shimosegawa. (2015) Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology Research 45:4, pages 363-377.
Crossref
Sumio Watanabe, Etsuko Hashimoto, Kenichi Ikejima, Hirofumi Uto, Masafumi Ono, Yoshio Sumida, Masataka Seike, Yoshiyuki Takei, Tetsuo Takehara, Katsutoshi Tokushige, Atsushi Nakajima, Masashi Yoneda, Toshiji Saibara, Goshi Shiota, Isao Sakaida, Makoto Nakamuta, Toshihiko Mizuta, Hirohito Tsubouchi, Kentaro Sugano & Tooru Shimosegawa. (2015) Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Journal of Gastroenterology 50:4, pages 364-377.
Crossref
Ajay Duseja, Shivaram P. Singh, Vivek A. Saraswat, Subrat K. Acharya, Yogesh K. Chawla, Subhankar Chowdhury, Radha K. Dhiman, Rohinivilasam V. Jayakumar, Kaushal Madan, Sri P. Misra, Hrudananda Mishra, Sunil K. Modi, Arumugam Muruganathan, Banshi Saboo, Rakesh Sahay & Rajesh Upadhyay. (2015) Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. Journal of Clinical and Experimental Hepatology 5:1, pages 51-68.
Crossref
Edyta Maslak, Piotr Zabielski, Kamila Kochan, Kamil Kus, Agnieszka Jasztal, Barbara Sitek, Bartosz Proniewski, Tomasz Wojcik, Katarzyna Gula, Agnieszka Kij, Maria Walczak, Małgorzata Baranska, Adrian Chabowski, Ryan J. Holland, Joseph E. Saavedra, Larry K. Keefer & Stefan Chlopicki. (2015) The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. Biochemical Pharmacology 93:3, pages 389-400.
Crossref
Aparna Bhat. (2015) Systematic review: Preventive and therapeutic applications of metformin in liver disease. World Journal of Hepatology 7:12, pages 1652.
Crossref
Yoshihisa Takahashi. (2015) Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology 21:13, pages 3777.
Crossref
S. Gitto, G. Vitale, E. Villa & P. Andreone. (2015) Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future. Gastroenterology Research and Practice 2015, pages 1-14.
Crossref
Susanne Tan, Nils Vollmar, Sven Benson, Jan-Peter Sowa, Lars P. Bechmann, Guido Gerken, Dagmar Fuhrer & Ali Canbay. (2015) Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. International Journal of Endocrinology 2015, pages 1-9.
Crossref
Le Thi Thanh Thuy, Hoang Hai & Norifumi Kawada. 2015. Studies on Hepatic Disorders. Studies on Hepatic Disorders 389 413 .
Dina L. Halegoua-De Marzio & Jonathan M. Fenkel. (2014) Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease. Advances in Hepatology 2014, pages 1-7.
Crossref
E. B. Mitchel & J. E. Lavine. (2014) Review article: the management of paediatric nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 40:10, pages 1155-1170.
Crossref
MINORU TOMIZAWA, YUJI KAWANABE, FUMINOBU SHINOZAKI, SUMIHIKO SATO, YASUFUMI MOTOYOSHI, TAKAO SUGIYAMA, SHIGENORI YAMAMOTO & MAKOTO SUEISHI. (2014) Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomedical Reports 2:5, pages 633-636.
Crossref
Laura Pala, Valeria Barbaro, Ilaria Dicembrini & Carlo Maria Rotella. (2014) The therapy of insulin resistance in other diseases besides type 2 diabetes. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity 19:3, pages 275-283.
Crossref
Shane A. Wells. (2014) Quantification of Hepatic Fat and Iron with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America 22:3, pages 397-416.
Crossref
Peter Dietrich & Claus Hellerbrand. (2014) Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice & Research Clinical Gastroenterology 28:4, pages 637-653.
Crossref
Eun Shil Hong, Eun Ky Kim, Seon Mee Kang, Ah Reum Khang, Sung Hee Choi, Kyong Soo Park, Hak Chul Jang & Soo Lim. (2014) Effect of carnitine‐orotate complex on glucose metabolism and fatty liver: A double‐blind, placebo‐controlled study. Journal of Gastroenterology and Hepatology 29:7, pages 1449-1457.
Crossref
Cory M. Fielding & Paul Angulo. (2014) Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?. Current Hepatology Reports 13:2, pages 151-158.
Crossref
Natalia Mazzella, Laura M. Ricciardi, Arianna Mazzotti & Giulio Marchesini. (2014) The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 18:1, pages 73-89.
Crossref
Zeynel Abidin Ozturk. (2014) Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World Journal of Hepatology 6:4, pages 199.
Crossref
Sara Heebøll. (2014) Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. World Journal of Hepatology 6:4, pages 188.
Crossref
Hye-jin Yoon. (2014) Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World Journal of Hepatology 6:11, pages 800.
Crossref
Bülent Baran. (2014) Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning?. World Journal of Gastroenterology 20:39, pages 14219.
Crossref
Mariana Verdelho Machado. (2014) Non-alcoholic fatty liver disease: What the clinician needs to know. World Journal of Gastroenterology 20:36, pages 12956.
Crossref

Displaying 200 of 246 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.